Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Correia de Simas Jose Manuel reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health officer Correia de Simas Jose Manuel received a grant of 17,637.8425 deferred stock units on Company common stock at a reference value of $23.36 per unit. Following this award, he holds 22,280.4709 deferred stock units. These units will be settled in cash or shares after employment ends or in a designated future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc officer Rajeev A. Modi reported a tax-related share disposition. On 2026-03-03, he disposed of 4,392 shares of common stock through a tax-withholding disposition at $24.88 per share, leaving 155,901 shares held with direct ownership after the transaction.
Elanco Animal Health Inc general counsel and corporate secretary Shiv O'Neill reported a Form 4 transaction involving company common stock. On March 3, 2026, O'Neill had 4,738 shares disposed of in a tax-withholding disposition at $24.88 per share, leaving 83,834 shares of directly owned common stock reported after the transaction. This disposition reflects shares withheld to cover tax obligations rather than an open-market sale.
Elanco Animal Health Inc President, CEO and Director Jeffrey N. Simmons reported a tax-withholding disposition of 37,898 shares of common stock on March 3, 2026. The disposition, coded as a payment of tax liability, was priced at $24.88 per share.
After this transaction, Simmons directly held 2,051,898 shares of Elanco common stock. A separate line shows an indirect holding of 167,000 shares held by a revocable trust, reported as indirect beneficial ownership.
Elanco Animal Health Inc officer Timothy J. Bettington reported a tax-withholding disposition of 4,695 shares of common stock on March 3, 2026. The shares were transferred at $24.88 per share to cover tax obligations, rather than sold in an open-market transaction. After this transaction, Bettington directly held 143,261 shares of Elanco common stock.
Elanco Animal Health officer Cabral Ramiro Martin reported a tax-withholding disposition of 6,492 shares of common stock at $24.88 per share on March 3, 2026. After this non-market transaction, he directly owned 283,874 common shares.
Elanco Animal Health Inc officer Jose Manuel Correia de Simas reported a tax-related share disposition. On March 3, 2026, he transferred 3,371 shares of common stock at $24.88 per share to cover tax withholding, and held 101,017 shares directly afterward.
Elanco Animal Health Inc executive Ellen de Brabander reported a tax-related stock transaction. On this Form 4, she disposed of 8,262 shares of Common Stock on March 3, 2026 through a tax-withholding disposition at a price of $24.88 per share, leaving her with 260,124 directly owned shares.
Elanco Animal Health Inc executive David S. Kinard reported a Form 4 transaction involving company common stock. On March 3, 2026, Kinard had a tax-related disposition of 3,433 shares of common stock at a reported price of $24.88 per share. This transaction is coded as a tax-withholding disposition, meaning shares were surrendered to cover tax obligations rather than being sold on the open market. After this transaction, Kinard directly held 214,264 shares of Elanco Animal Health Inc common stock.
Elanco Animal Health Inc executive Grace McArdle, EVP, Manufacturing and Quality, reported a tax-related share disposition. On March 3, 2026, she disposed of 4,322 shares of Elanco common stock at $24.88 per share in a transaction classified as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in an open-market trade. Following this transaction, she directly held 103,705 shares of Elanco common stock.